“When Angelina Jolie learns she has a breast cancer gene, we don’t know what else to do, so we cut her breasts off,” Dr. Susan Love, president of the Dr. Susan Love Research Foundation, recently told USA Today. “We have to be looking for the cause. I worry that we don’t, that we’re paying too much attention to the treatment, which comes with a huge cost.”
Interviewed about the new U.S. push to develop a breast cancer vaccine, Dr. Love was voicing the frustration many feel about the focus of U.S. cancer research and treatment. Appearing to lag their European peers, U.S. cancer researchers are only now recognizing the importance of immunotherapy in treating cancer. Jumping on the bandwagon, many U.S. university centers are exploring immunotherapy’s holistic, non-toxic approach to cancer treatment and beginning to offer trials of dendritic cell vaccines. Issels already has more than half a century of clinical experience with immunotherapy and years of proven experience using dendritic cell vaccines.
At the University of Pennsylvania, doctors recently began testing personalized cancer vaccines made with the patient’s own immune cells. As noted in the USA Today article, in the Pennsylvania test women with an early cancerous condition called ductal carcinoma in situ (DCIS) are being inoculated with an immunotherapy vaccine following surgical removal of breast tumors. It is hoped that the vaccination will prevent tumor recurrence; but trial participants will have to wait years before they know if the vaccine is effective.
At Issels you don’t have to wait. We already have a unique track record of long-term cancer remission results using cancer vaccines in integrative immunotherapy.